The project will finance the promoter's research and development (R&D) expenses for the development of a new cancer treatment. It concerns the clinical programme of a cancer vaccine for indications such as NSCLC (non-small-cell lung cancer), which is the major indication currently investigated, as well as trials for colorectal- , prostate- and breast cancer indications.
Objectives
It is the objective of this new cancer vaccine to stimulate the body's immune system to identify and destroy cancer cells.
Comments
Sector(s)
Industry
Proposed EIB finance (Approximate amount)
EUR 200 million
Total cost (Approximate amount)
EUR 625 million
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA) by a competent authority according to the Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC should not be required.
Procurement
The promoter is a private company not operating in the utilities sector, and is thus not covered by EU Directives on procurement.
Status
Approved
-
18/09/2012.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. Therefore data provided on this page is indicative and cannot be considered to represent official EIB Policy (see also the Explanatory notes).
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments regarding the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, EIB can also be contacted through its external offices.
Queries regarding details of a specific project, in particular when EIB loan is under appraisal, should be preferably addressed directly to project promoters.
Any complaint regarding alleged maladministration can be lodged to EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero-tolerance against fraud and corruption
The EIB has a zero-tolerance policy on fraud or corruption. To report allegations of fraud or corruption in EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential, and are handled in line with EIB investigation procedures and the Anti-Fraud Policy.
The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.
